Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This phase I study will evaluate the feasibility and toxicity of weekly bortezomib in the
treatment of relapsed or refractory multiple Myeloma and determine whether a twice-weekly
schedule of bortezomib is effective in producing responses in patients with stable disease or
progression after weekly bortezomib